| Literature DB >> 33400687 |
Eva M Stevenson1, Adam R Ward1,2,3, Ronald Truong2, Allison S Thomas4, Szu-Han Huang1,2, Thomas R Dilling1, Sandra Terry1, John K Bui1, Talia M Mota1, Ali Danesh1, Guinevere Q Lee1, Andrea Gramatica1, Pragya Khadka1, Winiffer D Conce Alberto1, Rajesh T Gandhi5, Deborah K McMahon6, Christina M Lalama7, Ronald J Bosch7, Bernard Macatangay6, Joshua C Cyktor6, Joseph J Eron8, John W Mellors6, R Brad Jones1,2.
Abstract
Antiretroviral therapies (ARTs) abrogate HIV replication; however, infection persists as long-lived reservoirs of infected cells with integrated proviruses, which reseed replication if ART is interrupted. A central tenet of our current understanding of this persistence is that infected cells are shielded from immune recognition and elimination through a lack of antigen expression from proviruses. Efforts to cure HIV infection have therefore focused on reactivating latent proviruses to enable immune-mediated clearance, but these have yet to succeed in reducing viral reservoirs. Here, we revisited the question of whether HIV reservoirs are predominately immunologically silent from a new angle: by querying the dynamics of HIV-specific T cell responses over long-term ART for evidence of ongoing recognition of HIV-infected cells. In longitudinal assessments, we show that the rates of change in persisting HIV Nef-specific responses, but not responses to other HIV gene products, were associated with residual frequencies of infected cells. These Nef-specific responses were highly stable over time and disproportionately exhibited a cytotoxic, effector functional profile, indicative of recent in vivo recognition of HIV antigens. These results indicate substantial visibility of the HIV-infected cells to T cells on stable ART, presenting both opportunities and challenges for the development of therapeutic approaches to curing infection.Entities:
Keywords: AIDS/HIV; Immunology; T cells
Year: 2021 PMID: 33400687 PMCID: PMC7934865 DOI: 10.1172/jci.insight.142640
Source DB: PubMed Journal: JCI Insight ISSN: 2379-3708